kaisx
2021-11-23
Like. Pls
Progenity strengthens liquidity position capable enough to achieve R&D milestones through 2022
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":875573464,"tweetId":"875573464","gmtCreate":1637675267813,"gmtModify":1637675267813,"author":{"id":3584869808763617,"idStr":"3584869808763617","authorId":3584869808763617,"authorIdStr":"3584869808763617","name":"kaisx","avatar":"https://static.tigerbbs.com/40adae7177ebef40c5a18d202e8b58ea","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":16,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like. Pls</p></body></html>","htmlText":"<html><head></head><body><p>Like. Pls</p></body></html>","text":"Like. Pls","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/875573464","repostId":1188126714,"repostType":4,"repost":{"id":"1188126714","pubTimestamp":1637675025,"share":"https://www.laohu8.com/m/news/1188126714?lang=&edition=full","pubTime":"2021-11-23 21:43","market":"us","language":"en","title":"Progenity strengthens liquidity position capable enough to achieve R&D milestones through 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1188126714","media":"seekingalpha","summary":"Progenity(NASDAQ:PROG)strengthened its liquidity position as it reported ~$44M in warrant exercises ","content":"<p>Progenity(NASDAQ:PROG)strengthened its liquidity position as it reported ~$44M in warrant exercises to date during Q4.</p>\n<p>Through an exchange transaction in Q4, the company reduced by 38% the principal amount of its convertible senior notes due 2025 held by non-affiliates, with the majority of the remaining balance held by an affiliated holder, Athyrium Capital Management.</p>\n<p>The current liquidity position provides runway to achieve critical research and development milestones through 2022.</p>\n<p>\"In a very short period of time, we’ve simplified our operations and focused our capital allocation to transform Progenity into a biotherapeutics company. We expect further improvement in operating expenditures as we continue to execute our transformation and focus on expediting development of our gastrointestinal health and oral biotherapeutics programs,\" CEO Adi Mohanty commented.</p>\n<p>Shares trading 3.8% down premarket</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Progenity strengthens liquidity position capable enough to achieve R&D milestones through 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProgenity strengthens liquidity position capable enough to achieve R&D milestones through 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-23 21:43 GMT+8 <a href=https://seekingalpha.com/news/3773706-progenity-strengthens-liquidity-position-capable-enough-to-achieve-rd-milestones-through-2022><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Progenity(NASDAQ:PROG)strengthened its liquidity position as it reported ~$44M in warrant exercises to date during Q4.\nThrough an exchange transaction in Q4, the company reduced by 38% the principal ...</p>\n\n<a href=\"https://seekingalpha.com/news/3773706-progenity-strengthens-liquidity-position-capable-enough-to-achieve-rd-milestones-through-2022\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3773706-progenity-strengthens-liquidity-position-capable-enough-to-achieve-rd-milestones-through-2022","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1188126714","content_text":"Progenity(NASDAQ:PROG)strengthened its liquidity position as it reported ~$44M in warrant exercises to date during Q4.\nThrough an exchange transaction in Q4, the company reduced by 38% the principal amount of its convertible senior notes due 2025 held by non-affiliates, with the majority of the remaining balance held by an affiliated holder, Athyrium Capital Management.\nThe current liquidity position provides runway to achieve critical research and development milestones through 2022.\n\"In a very short period of time, we’ve simplified our operations and focused our capital allocation to transform Progenity into a biotherapeutics company. We expect further improvement in operating expenditures as we continue to execute our transformation and focus on expediting development of our gastrointestinal health and oral biotherapeutics programs,\" CEO Adi Mohanty commented.\nShares trading 3.8% down premarket","news_type":1},"isVote":1,"tweetType":1,"viewCount":458,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/875573464"}
精彩评论